Cargando…

2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate

BACKGROUND: Antibiotic resistance is associated with a fitness cost and reduced bacterial growth that allows susceptible bacteria to outcompete resistant bacteria, if selective pressure from antibiotics is reduced. Ceftolozane/tazobactam (C/T) approved in 2014, was temporarily withdrawn from Decembe...

Descripción completa

Detalles Bibliográficos
Autores principales: Imeneo, Alessandra, Campogiani, Laura, Di Lorenzo, Andrea, D’Agostini, Cartesio, Altieri, Anna, Malagnino, Vincenzo, Andreoni, Massimo, Iannetta, Marco, Sarmati, Loredana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677637/
http://dx.doi.org/10.1093/ofid/ofad500.1791
_version_ 1785150177009467392
author Imeneo, Alessandra
Campogiani, Laura
Di Lorenzo, Andrea
D’Agostini, Cartesio
Altieri, Anna
Malagnino, Vincenzo
Andreoni, Massimo
Iannetta, Marco
Sarmati, Loredana
author_facet Imeneo, Alessandra
Campogiani, Laura
Di Lorenzo, Andrea
D’Agostini, Cartesio
Altieri, Anna
Malagnino, Vincenzo
Andreoni, Massimo
Iannetta, Marco
Sarmati, Loredana
author_sort Imeneo, Alessandra
collection PubMed
description BACKGROUND: Antibiotic resistance is associated with a fitness cost and reduced bacterial growth that allows susceptible bacteria to outcompete resistant bacteria, if selective pressure from antibiotics is reduced. Ceftolozane/tazobactam (C/T) approved in 2014, was temporarily withdrawn from December 2020 to February 2022: this forced unavailability created the conditions to study how drug discontinuation might influence resistance reversibility. METHODS: This is a retrospective observational study, including isolates of P. aeruginosa collected between March 1(st) 2019 and February 22(nd) 2023. Isolates collected from swabs (e.g. rectal, skin) or with no C/T susceptibility test were excluded. Antibiotic susceptibility tests were performed with the Vitek-2 assay. Only the first isolate for each patient was included; multiple isolates from the same patient were included if collected at least 5 months apart. Four collection periods were defined (Fig 1). All data were analyzed using JASP. [Figure: see text] RESULTS: From the Hospital microbiology laboratory list, 1768 P. aeruginosa isolates were derived, of which 926 isolates fulfilled the inclusion criteria. A significant (p-value < 0.001) reduction of C/T resistance rate was observed when the antibiotic was unavailable, followed by a subsequent increase with its reintroduction (Tab.1). Evaluating phenotypic susceptibility to other antibiotics, production of GES-variants, suggested by resistance to carbapenem and C/T but retained susceptibility to ceftazidime/avibactam, was most likely the predominant resistance mechanism (Tab. 2); a reduction in GES-like isolates, concurrent with decreasing C/T resistance was observed. 19 patients presented a C/T-resistant isolate after a previous susceptible one, but only 4 patients had received a prior C/T treatment (Tab 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: The temporary unavailability of C/T created the condition to analyze the practical application of the theory of fitness cost to maintain resistance. Our data show a significant reduction of resistance in the absence of the antibiotic, but a subsequent increase with its reintroduction, due to the persistence of resistant isolates. Therefore, continuous monitoring of antibiotic use and evolving resistance is essential. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677637
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106776372023-11-27 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate Imeneo, Alessandra Campogiani, Laura Di Lorenzo, Andrea D’Agostini, Cartesio Altieri, Anna Malagnino, Vincenzo Andreoni, Massimo Iannetta, Marco Sarmati, Loredana Open Forum Infect Dis Abstract BACKGROUND: Antibiotic resistance is associated with a fitness cost and reduced bacterial growth that allows susceptible bacteria to outcompete resistant bacteria, if selective pressure from antibiotics is reduced. Ceftolozane/tazobactam (C/T) approved in 2014, was temporarily withdrawn from December 2020 to February 2022: this forced unavailability created the conditions to study how drug discontinuation might influence resistance reversibility. METHODS: This is a retrospective observational study, including isolates of P. aeruginosa collected between March 1(st) 2019 and February 22(nd) 2023. Isolates collected from swabs (e.g. rectal, skin) or with no C/T susceptibility test were excluded. Antibiotic susceptibility tests were performed with the Vitek-2 assay. Only the first isolate for each patient was included; multiple isolates from the same patient were included if collected at least 5 months apart. Four collection periods were defined (Fig 1). All data were analyzed using JASP. [Figure: see text] RESULTS: From the Hospital microbiology laboratory list, 1768 P. aeruginosa isolates were derived, of which 926 isolates fulfilled the inclusion criteria. A significant (p-value < 0.001) reduction of C/T resistance rate was observed when the antibiotic was unavailable, followed by a subsequent increase with its reintroduction (Tab.1). Evaluating phenotypic susceptibility to other antibiotics, production of GES-variants, suggested by resistance to carbapenem and C/T but retained susceptibility to ceftazidime/avibactam, was most likely the predominant resistance mechanism (Tab. 2); a reduction in GES-like isolates, concurrent with decreasing C/T resistance was observed. 19 patients presented a C/T-resistant isolate after a previous susceptible one, but only 4 patients had received a prior C/T treatment (Tab 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: The temporary unavailability of C/T created the condition to analyze the practical application of the theory of fitness cost to maintain resistance. Our data show a significant reduction of resistance in the absence of the antibiotic, but a subsequent increase with its reintroduction, due to the persistence of resistant isolates. Therefore, continuous monitoring of antibiotic use and evolving resistance is essential. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677637/ http://dx.doi.org/10.1093/ofid/ofad500.1791 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Imeneo, Alessandra
Campogiani, Laura
Di Lorenzo, Andrea
D’Agostini, Cartesio
Altieri, Anna
Malagnino, Vincenzo
Andreoni, Massimo
Iannetta, Marco
Sarmati, Loredana
2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title_full 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title_fullStr 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title_full_unstemmed 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title_short 2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
title_sort 2169. a 4-year analysis of antimicrobial susceptibility to ceftolozane/tazobactam in pseudomonas aeruginosa: how drug availability affects resistance rate
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677637/
http://dx.doi.org/10.1093/ofid/ofad500.1791
work_keys_str_mv AT imeneoalessandra 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT campogianilaura 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT dilorenzoandrea 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT dagostinicartesio 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT altierianna 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT malagninovincenzo 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT andreonimassimo 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT iannettamarco 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate
AT sarmatiloredana 2169a4yearanalysisofantimicrobialsusceptibilitytoceftolozanetazobactaminpseudomonasaeruginosahowdrugavailabilityaffectsresistancerate